• Company
• Expectations rise for prescription of tumor-agnostic drugs
• by Eo, Yun-Ho Jan 3, 2022 05:56am

• Product
• Is the price of Paxlovid reasonable?
• by Jan 3, 2022 05:55am

• Company
• Samsung Biologics denies rumors of Biogen's acquisition
• by Jan 3, 2022 05:55am

• Company
• Record number of new homegrown drugs released this year
• by Chon, Seung-Hyun Dec 31, 2021 05:51am

• Company
• Daewoong's drug targets ₩100 bil market as 2nd P-CAB
• by Kim, Jin-Gu Dec 31, 2021 05:51am

• Company
• Competition for KRAS targeted anticancer drugs
• by Dec 31, 2021 05:51am

• Policy
• Changes in Benefit standards such as diabetes drugs
• by Kim, Jung-Ju Dec 31, 2021 05:50am

• Company
• Introduction of oral tx for COVID-19
• by Whang, byung-woo Dec 31, 2021 05:50am

• Company
• Xospata's drug price negotiation period has been extended
• by Eo, Yun-Ho Dec 30, 2021 05:51am

• Company
• K-pharma·biopharmas make great tech export deals this year
• by Chon, Seung-Hyun Dec 30, 2021 05:51am